or Try an Advanced Search...

    Glucose Meter Stocks List

    Symbol Grade Name % Change
    SNY B Sanofi 2.51
    TNDM B Tandem Diabetes Care, Inc. -4.12
    View As Page of Charts
    Related Industries: Drug Manufacturers - Major Medical Devices
    Related Stock Lists: Glucose Insulin Animal Health Cac 40 Cancer Caregiver Chronic Kidney Disease Clopidogrel Colorectal Cancer Consumer Health Care Consumer Health Care Products Deep Vein Thrombosis Diabetes Diabetes Care Diabetes Management Diabetes Mellitus Diabetes Mellitus Type 1 Dialysis Endocrine System Endocrinology

    Related ETFs - A few ETFs which own one or more of the above listed Glucose Meter stocks.

    Symbol Grade Name Weight
    EDOC F Global X Telemedicine & Digital Health ETF 5.14
    PPH B Market Vectors Pharmaceutical ETF 4.61
    VIRS C Pacer BioThreat Strategy ETF 4.08
    FDHT D Fidelity Digital Health ETF 3.51
    PID A PowerShares Intl Dividend Achievers 2.88
    View all Glucose Meter ETFs...
    Compare ETFs
    Compare EDOC to PPH Compare EDOC to VIRS Compare VIRS to FDHT

        Glucose Meter Stocks Recent News

        Date Stock Title
        Jun 1 TNDM At US$51.23, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?
        May 31 SNY FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
        May 31 SNY FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
        May 31 SNY Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
        May 31 SNY Regeneron/ Sanofi say FDA has delayed Dupixent COPD label
        May 31 SNY Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
        May 31 SNY Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
        May 31 SNY Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
        May 31 SNY Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
        May 31 SNY Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
        May 30 TNDM Insulet, Tandem new buys from Redburn Atlantic in diabetes technology space
        May 30 TNDM Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor
        May 30 SNY Press Release: Sanofi completes acquisition of Inhibrx, Inc.
        May 29 SNY VeeCon 2024 Speakers Announced: X CEO Linda Yaccarino, Content Creator Khaby Lame, Gary Vee Among Special Guests To Appear At Festival That Combines Business, Pop Culture, Web3
        May 29 TNDM Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM
        May 29 TNDM Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here
        May 29 SNY Sanofi’s CEO is giving OpenAI access to its data in the hope of developing drugs more quickly
        May 29 SNY 3 High-Yielding Dividend Stocks On Euronext Paris With Up To 4.2% Yield
        May 28 SNY FDA accepts Sanofi’s Sarclisa sBLA for priority review
        May 27 SNY Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
        Related Industries: Drug Manufacturers - Major Medical Devices
        Related Stock Lists: Glucose Insulin Animal Health Cac 40 Cancer Caregiver Chronic Kidney Disease Clopidogrel Colorectal Cancer Consumer Health Care Consumer Health Care Products Deep Vein Thrombosis Diabetes Diabetes Care Diabetes Management Diabetes Mellitus Diabetes Mellitus Type 1 Dialysis Endocrine System Endocrinology
        Glucose Meter

        A glucose meter is a medical device for measuring the amount of glucose in the blood. It is a key element of home blood glucose monitoring (HBGM) by people with diabetes mellitus or hypoglycemia. A small drop of blood, obtained by pricking the skin with a lancet, is placed on a disposable test strip that the meter reads and uses to calculate the blood glucose level. The meter then displays the level in mg/dl or mmol/l.

        Browse All Tags